Predicting fatty liver with body weight and blood test
Part of Hormones & metabolism clinical trials.
This study is looking for a simple way to detect fat buildup in the liver (fatty liver) using a ratio calculated from your blood creatinine level and your body weight. If you have metabolic syndrome, they want to see if this ratio can predict fatty liver, which may help with earlier detection without needing extra scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have metabolic syndrome (which means having at least 3 of: high waist size, high blood fat, low 'good' cholesterol, high blood pressure, or high blood sugar).
- You must not have other liver diseases (like hepatitis B or C) or serious alcohol use.
- You must not have significant kidney disease or be on dialysis.
- You must not be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple blood test can help detect fatty liver disease in people who have metabolic syndrome. It may offer a less invasive way to identify liver problems early.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study looks at whether a simple blood test (FIB-4) can help detect liver scarring in people with obesity. It may help doctors identify liver problems earlier.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This study aims to build a tool to predict how MASLD-related cirrhosis (fatty liver disease leading to liver scarring) will progress. It may help doctors and patients better understand the outlook and plan care.
Hear when a new Metabolic Syndrome (MetS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.